On this page
orphan disease
Explore "orphan disease" with insightful episodes like "Krankheit ohne Namen - Kinder mit Seltenen Krankheiten profitieren von Psycho-Edukation", "Neurology meets Rheumatology – Schnittstellen, Synergien & mehr", "Generalisierte Myasthenia gravis – die aktuelle Leitlinie im klinischen Kontext", "Ein Wiener Pharmaunternehmen investiert in Therapien für seltene Erkrankungen" and "Das ultraseltene Loeys-Dietz-Syndrom" from podcasts like ""Hörgang", "Let's talk Neuro: Der Podcast zur Neuroimmunologie", "Let's talk Neuro: Der Podcast zur Neuroimmunologie", "Hörgang" and "Hörgang"" and more!
Episodes (11)
Neurology meets Rheumatology – Schnittstellen, Synergien & mehr
Generalisierte Myasthenia gravis – die aktuelle Leitlinie im klinischen Kontext
Ein Wiener Pharmaunternehmen investiert in Therapien für seltene Erkrankungen
Das ultraseltene Loeys-Dietz-Syndrom
Xénia Proton de la Chapelle, fondatrice d'AtmosR
Destins croisés. Rien ne prédestinait Xénia Proton de la Chapelle à fonder AtmosR. Issue d'une école de commerce, elle n'avait fait que caresser l'idée de devenir chercheuse avant de se lancer dans des études de commerce.
Pas de fatalité. La naissance de son quatrième enfant, atteint de la maladie d'Ondine, une pathologie orpheline, a tout changé. Si aucun traitement n'existait alors, elle a décidé de contribuer à en inventer une.
Ecoutez son histoire. La certitude de pouvoir s'appuyer sur des travaux de recherche, sa force de caractère, sa capacité à savoir s'entourer et un peu de chance l'ont donc mené à la Deeptech sans le vouloir.
Myasthenia gravis – Auf und Ab im Leben der Betroffenen
Uniquely singular: Exploring what it means to be rare
Pick any two humans on Earth and analysis will show that their DNA is around 99.9% identical. But that tiny 0.1% difference, in combination with our environment, is what makes us unique. We each have a singular experience of the world—the interactions we have, the food we eat, the diseases we suffer. In this final webinar in our 2021 series on rare diseases, we will take a critical look at the importance of understanding our rarity and uniqueness as a way to understand the human condition, our needs, and health. We will explore the importance of being “rare” and move past our innate desire for homogeneity and the comfort of conformity, to embrace heterogeneity and difference. Valuing differences is a pathway to growth and progress as individuals and societies. Having explored the unique challenges of people with rare diseases, might we argue that all disease is unique for the person who endures it?
With:
Ioannis Thomas Pavlidis, Ph.D. (University of Houston, Houston, Texas)
Inês Pires Santos Ramos Pinheiro, Ph.D. (Institut Curie, Paris, France)
Judith S. Kaur, M.D. (Mayo Clinic, Jacksonville, Florida)
Terrence Forrester, M.D., Ph.D. (The University of the West Indies, Kingston, Jamaica)
What’s the plan? From detection to diagnosis to treatment of rare diseases
If our ability to test for and detect rare diseases can be significantly
improved, a predictable future challenge will be that patients are
diagnosed but there is no available means or expertise to provide
optimal treatment and ongoing support. In this webinar, we will discuss
strategies for solving this issue, including how data collected by
international consortia in diverse settings might inform possible
solutions, and how these solutions might be implemented.
With:
Domenica Taruscio, M.D. (National Centre for Rare Diseases, Rome, Italy)
Tim Guilliams, Ph.D. (Healx, Cambridge, UK)
David A Pearce, Ph.D. (Sanford Health, Sioux Falls, SD)
Marta Mosca, M.D., Ph.D. (University of Pisa, Pisa, Italy)
Sean Sanders, Ph.D. (Science/AAAS, Washington, DC)
This podcast was adapted from a webinar launched by Science Magazine, with the support of Fondation Ipsen.
MS oder doch NMOSD?
Neonatal testing for rare diseases: The power of knowing
While in concept it is straightforward to develop a neonatal testing panel for rare (and common) diseases, the greater challenges are in the dissemination of this panel and the training of medical personnel concerning what to do with the information. Neonatal testing represents a weapon for early detection of rare disease, but implementation is key. Additionally, how the results are shared with patients and what actions are taken based on those results are critical. Join this discussion to learn from experts about the pros and cons of neonatal (and prenatal) testing for rare diseases and what challenges face both the medical community treating these disorders and the patients living with them.
With:
Monica Wojcik, M.D. (Boston Children's Hospital & Harvard Medical School ; Boston, MA)
Roberto Giugliani, M.D., Ph.D. (Federal University of Rio Grande do Sul ; Porto Alegre, Brazil)
Melissa P. Wasserstein, M.D. (The Children's Hospital at Montefiore ; Bronx, NY)
James R. Bonham, Ph.D. (International Society for Neonatal Screening ; Maarssen, The Netherlands)
Sean Sanders, Ph.D. (moderator ; Science/AAAS ; Washington, DC)
This podcast is the audio recording of a webinar launched by Science magazine, with the support of Fondation Ipsen.